Clinical Solutions LLC, a global provider of digital clinical software and services, will bring together prominent technology ...

from storing safe data to speeding up clinical trials and ultimately lowering drug development costs. With enormous amounts of clinical trial data being generated every day, and pressures from ...

Your business strategy may involve developing the methods required for mass production, storage, distribution, and clinical ... value chain requires an effort similar to that required for the ...

Walgreens is the latest US retail pharmacy giant to have a go at disrupting the clinical trials industry, with the launch of a new business unit that will tap into its reserve of patient data ...

Orchestration strategies enable disparate supply chain resources ... products through our development pipeline. But other forms of AI are already delivering value, and the data products described ...

McKesson launches InspiroGene by McKesson, a dedicated business focused solely on supporting the commercialization of cell ...

Massive Bio, a global leader in artificial intelligence (AI) for cancer clinical trial enrollment, has announced the launch of Patient Connect, an inn ...

“In an effort to reflect the strong development of the company, now covering the full value-added chain of data center development, the new brand DCP highlights the organization’s commitment to ...

As we enter a critical phase in our company’s journey, Mainz Biomed’s vision remains focused on leading the way in cancer diagnostics,” said Guido Baechler, CEO of Mainz Biomed. “Our groundbreaking ...

There are extra challenges and regulatory complexities that must be fully understood before integrating drones into your clinical supply chain ... The ongoing development of drone technology ...

In addition, Formycon will present study data focusing on the pharmacokinetics of the ustekinumab biosimilar candidate FYB202 at the United European Gastroenterology (UEG) Week from October 12 to 15, ...

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 ...